摘要
为研究以基因转移技术治疗血栓性疾病的可能性，将３０只普通级雄性昆明小鼠随机均分为６组，第１～４组腹腔注射含人小分子量尿激酶（ｍＵＫ）基因的重组质粒ｐｃＤＮＡ３ｍＵＫ，剂量分别为２０、４０、６０和８０ｕｇ／只；第５、６组为对照，分别注射ｐｃＤＮＡ３和转染液。血浆ｍＵＫ活性用Ｓ２３９Ｏ发色底物分光光度法测定。注射后，对照组的血浆ｍＵＫ活性无显著变化；第１～４组的ｍＵＫ活性逐渐升高，第１０天达高峰，峰值分别为１４００±１７０、２２００±２２０、３０５０±３４０和３３５０±２６０ＩＵ／Ｌ。后３组的ｍＵＫ活性显著高于注射前（９４０±２００ＩＵ／Ｌ，ｎ＝３０），至注射后６０ｄ，仍显著高于注射前（Ｐ＜０．０５）。这表明裸露质粒腹腔内注射能升高小鼠血浆纤溶活性，可能为血栓性疾病的防治提供新途径。
The possibility of treating thrombosis diseases by gene transfer was studied witheukaryotic 'expression vector containing human mUK cDNA. Thirty Kunmingmice were divided into 6 grouPS. The doses (ip) of pcDNA 3 mUK in group 1-4were 20, 40, 60,80 ug/mouse respectively. The other 2 groups were injected intraPeritoneally with pcDNA 3 and transfection solution respectively as controls. Theplasma mUK activity was measured with synthetic-peptide substrate S2390. They increased significantly(P<0.05)in group 2-4 from the 5th to the 60th day after theinjection as compared with those before the injection (940±200 IU/L, n = 30), andreached the peaks of 2200±220, 3050±340, 3350±260 In/L respectively 10 daysafter the injection. The result suggests that the method of injection with recombinantplasmid containing human mUK cDNA may be applied to the prevention andtreatment of thrombosis diseases.
出处
《上海实验动物科学》
1995年第4期193-197,共5页
Shanghai Laboratory Animal Science
基金
上海医科大学基因治疗基金
关键词
尿激酶
小分子量尿激酶
重组质粒
基因转移
药理
Micro-urokinase Recombinant plasmid Gene transfer Plasma fibrinolytic activity Mouse
